Drugs / TEZ/IVA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03224351 | Aug 2017 → Feb 2018 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZ/IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03224351 ↗ |
| Action | Restore | “developed to restore the function of Phe508del CFTR protein” PMID 30334693 ↗ Oct 2018 |
| Route | Oral | “TEZ/IVA fixed-dose combination tablet for oral administration.” NCT03224351 ↗ |
| Target | CFTR | “restore the function of Phe508del CFTR protein” PMID 30334693 ↗ Oct 2018 |